Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

enVVeno Medical Corporation - Common Stock (NQ:NVNO)

2.600 +0.010 (+0.39%)
Streaming Delayed Price Updated: 9:39 AM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about enVVeno Medical Corporation - Common Stock

< Previous 1 2 3 Next >
The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium
Via ACCESS Newswire
enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25
Via ACCESS Newswire
enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Via ACCESS Newswire
One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum
Via ACCESS Newswire
Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting
Via ACCESS Newswire
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe
Via ACCESSWIRE
enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website
Via ACCESSWIRE
enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium
Via ACCESSWIRE
enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval
Via ACCESSWIRE
enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year
Via ACCESSWIRE
enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)
Via ACCESSWIRE
BioMedNewsBreaks — enVVeno Medical Corporation (NASDAQ: NVNO) Announces Pricing of $15M Underwritten Public Offering
Via Investor Brand Network
enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering
Via ACCESSWIRE
enVVeno Medical Corporation Announces Proposed Public Offering
Via ACCESSWIRE
enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing
Via ACCESSWIRE
enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R)
Via ACCESSWIRE
enVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Via ACCESSWIRE
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series
Via ACCESSWIRE
Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024 Vascular Annual Meeting
Via ACCESSWIRE
New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024
Via ACCESSWIRE
enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update
Via ACCESSWIRE
enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
Via ACCESSWIRE
enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity
Via ACCESSWIRE
enVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposium
Via ACCESSWIRE
enVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
Via ACCESSWIRE
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting
Via ACCESSWIRE
enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024
Via ACCESSWIRE
enVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium
Via ACCESSWIRE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS